Jade Biosciences — Third Quarter 2026 Earnings Summary

Jade Biosciences reported a net loss of $35.1 million for the third quarter ended September 30, 2026, driven by increased research and development and general and administrative expenses. The company holds $475.7 million in cash, cash equivalents, and investments, providing a runway into the fourth quarter of 2028. Key pipeline updates include the expected initiation of the Phase 3 EVERGREEN trial for JADE101 in the fourth quarter of 2026 and the planned start of the Phase 1 JADE301 trial in dermatomyositis during the same period. Additionally, the company expanded Brad Dahms' role to include Chief Business Officer responsibilities alongside his position as Chief Financial Officer.